Werewolf Therapeutics, INC 8-K filings

Werewolf Therapeutics reported Q2 2026 financial results, including $21.0 million in collaboration revenue from an asset sale, and provided an update on its strategic alternatives process.

Werewolf Therapeutics reported Q1 2026 results, announcing an asset purchase agreement with Jazz Pharmaceuticals for JZP898 and a repayment of debt, alongside reduced net losses.

Werewolf Therapeutics announced its fourth quarter and full year 2025 financial results and initiated a process to explore strategic alternatives to maximize stockholder value.

Werewolf Therapeutics, Inc. announced it will explore a full range of strategic alternatives to maximize stockholder value, engaging Piper Sandler & Co. as its exclusive financial advisor.

Werewolf Therapeutics announced a significant workforce reduction of 64%, the departure of its CFO and CMO, and ongoing efforts to secure capital and strategic partnerships.

Werewolf Therapeutics, Inc. received a deficiency letter from Nasdaq due to its common stock trading below the $1.00 minimum bid price requirement.

Werewolf Therapeutics announces compelling Phase 1/1b data for WTX-124 and WTX-330 INDUKINE programs, alongside progress on its INDUCER T-cell engager platform, while seeking strategic partnerships and additional funding.

Werewolf Therapeutics announced its third-quarter 2025 financial results and provided key updates on its clinical and preclinical oncology programs, including Fast Track Designation for WTX-124.

Werewolf Therapeutics reports the passing of a key board member, leading to non-compliance with Nasdaq's Audit Committee requirements, but outlines a plan to regain compliance.

Werewolf Therapeutics reported second quarter 2025 financial results, highlighted by clinical trial progress for WTX-124 and WTX-330, and the introduction of a new T-cell engager candidate, WTX-1011.

Werewolf Therapeutics, Inc. announced the adoption of amended bylaws to enhance corporate governance and reported the successful election of three Class I directors and the ratification of Ernst & Young LLP as its independent auditor at its annual stockholder meeting on June 12, 2025.

Werewolf Therapeutics received a notice from Nasdaq indicating that its common stock price has fallen below the minimum bid price requirement of $1.00 per share for continued listing.

Werewolf Therapeutics announces positive Q1 2025 financial results, highlighted by progress in clinical trials for WTX-124 and WTX-330, and the development of INDUCER T cell engager molecules.

Werewolf Therapeutics announces its Q4 and full-year 2024 financial results, highlighting progress in clinical trials for WTX-124 and WTX-330 and providing a business update.

Werewolf Therapeutics announces the resignation of director Derek DiRocco and the appointment of Anil Singhal to its Board of Directors.

Werewolf Therapeutics shared an updated corporate presentation, showcasing progress in their clinical programs and highlighting the potential of their INDUKINE platform.

Werewolf Therapeutics reported its Q3 2024 financial results and shared encouraging clinical and preclinical data for its INDUKINE platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Werewolf Therapeutics reported encouraging clinical trial data for its WTX-124 and WTX-330 programs, along with its second quarter 2024 financial results.

Werewolf Therapeutics reports encouraging early data from its Phase 1 trial of WTX-330, showing improved tolerability and clinical activity in advanced cancer patients.

Werewolf Therapeutics reported encouraging preliminary clinical data from its Phase 1/1b trial of WTX-124, showing clinical activity and a favorable safety profile in patients with advanced solid tumors.

Werewolf Therapeutics held its annual stockholder meeting on May 24, 2024, where directors were elected and the appointment of the independent auditor was ratified.

Werewolf Therapeutics reported its first quarter 2024 financial results, highlighted by a cash runway extension through at least the first quarter of 2026 and upcoming clinical data presentations.

Werewolf Therapeutics reported its Q4 and full year 2023 financial results, highlighted by a cash runway extended through at least Q2 2025 and upcoming clinical data presentations.

Werewolf Therapeutics has filed a prospectus supplement to offer up to $25 million of its common stock, following the completion of a previous $50 million offering.